GRI Bio, Inc.
NasdaqCM:GRI Stock Report
GRI Bio Balance Sheet Health
Financial Health criteria checks 4/6 GRI Bio has a total shareholder equity of $4.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $7.0M and $2.3M respectively.
Key information Interest coverage ratio n/a Cash US$6.35m Equity US$4.72m Total liabilities US$2.31m Total assets US$7.03m
Recent financial health updates
GRI Bio, Inc. Receives Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement Sep 11
GRI Bio Regains Compliance with Nasdaq Jul 09 GRI Bio Announces Update on Deficiency Letter from Nasdaq Regarding Minimum Stockholders’ Equity Requirement May 23
GRI Bio Approves 1-for-7 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Jan 27
GRI Bio Receives Non-Compliance Notice From Nasdaq Nov 27
GRI Bio Receives Non-Compliance Notice From Nasdaq Nov 26
Show all updates
GRI Bio, Inc. Receives Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement Sep 11
GRI Bio, Inc., Annual General Meeting, Aug 23, 2024 Jul 24
GRI Bio Regains Compliance with Nasdaq Jul 09
GRI Bio, Inc. Announces Publication of Positive Preclinical Data from Lead Program GRI -0621 in the American Journal of Respiratory and Critical Care Medicine Jul 02 GRI Bio, Inc. has filed a Follow-on Equity Offering. Jun 20
GRI Bio Announces Update on Deficiency Letter from Nasdaq Regarding Minimum Stockholders’ Equity Requirement May 23
GRI Bio, Inc. has filed a Follow-on Equity Offering in the amount of $0.961579 million. May 21
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent Apr 19
GRI Bio, Inc. Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom Mar 05
GRI Bio Approves 1-for-7 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Jan 27 GRI Bio, Inc. has filed a Follow-on Equity Offering in the amount of $16 million. Dec 22
New major risk - Share price stability Dec 06
GRI Bio, Inc. Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for Treatment of Idiopathic Pulmonary Fibrosis Dec 05 GRI Bio, Inc. Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis Nov 29
GRI Bio, Inc. Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis Nov 28
GRI Bio Receives Non-Compliance Notice From Nasdaq Nov 27
GRI Bio Receives Non-Compliance Notice From Nasdaq Nov 26
New major risk - Financial position Nov 17
New major risk - Market cap size Aug 09
GRI Bio, Inc., Annual General Meeting, Jul 07, 2023 May 27
Financial Position Analysis
Short Term Liabilities: GRI's short term assets ($6.9M) exceed its short term liabilities ($2.2M).
Long Term Liabilities: GRI's short term assets ($6.9M) exceed its long term liabilities ($96.0K).
Debt to Equity History and Analysis
Debt Level: GRI is debt free.
Reducing Debt: GRI had no debt 5 years ago.
Cash Runway Analysis For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GRI has less than a year of cash runway based on its current free cash flow .
Forecast Cash Runway: GRI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 74.5% each year
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}